Onco Actu du 22 juin 2015

	2. Etiologie
Frederick P. Li, Who Proved a Genetic Cancer Link, Dies at 75 [NY Times] Mutations in the same gene are also involved in many types of cancer that are not part of the Li-Fraumeni syndrome, so studying families that have the syndrome can yield information about cancer biology that may have broad implications, Dr. Fraumeni said.
	3.1 Tabac
Hawaii becomes first U.S. state to raise smoking age to 21 [Reuters] The law takes effect on Jan. 1, 2016, and will also ban the sale, purchase or use of electronic cigarettes for those under the age of 21.
NCI funds $3.1M Fred Hutch clinical trial of smoking-cessation smartphone app [Fred Hutch] First such study to compare effectiveness of quit-smoking programs delivered via mobile apps.
	4.10 Dép., diag. & prono. - Poumon
Gene Classifier May Help to Diagnose Lung Cancer [National Cancer Institute] Overall, the sensitivity of bronchoscopy plus the classifier was 97 percent compared with 75 percent for bronchoscopy alone. The sensitivity of the combination test was consistently high across nodule size, location, cancer stage, or type, they reported. The genomic classifier incorrectly suggested cancer in 53 percent of people who did not have lung cancer.
	4.5 Dép., diag. & prono. - Colorectal
Lifting the lid on bowel screening – why doesn’t everyone invited take part? [Cancer Research UK] Initiatives like these are uncovering the most effective ways to increase uptake. It’s vital, life-saving work.
	5. Traitements
Overcoming Drug Resistance: The EGFR Enigma [CANCER RESEARCH Catalyst] A series of peer-reviewed papers published in the AACR journals Clinical Cancer Research and Cancer Discovery have dissected the mechanisms of resistance to anti-EGFR therapies and investigated different approaches to outsmarting drug resistance.
	5.2 Pharma
CYRAMZA® (ramucirumab) Hepatocellular Carcinoma Data Published by The Lancet Oncology [Lilly] Encouraging Subgroup Findings Are Basis for New Phase III Trial.
Cyramza Falls Short in Phase III; Lilly to Launch New Trial in Subgroup [GEN] REACH is a global, randomized, double-blind study that began in 2010 and has enrolled 565 patients in 27 countries. REACH compared Cyramza plus best supportive care to placebo and best supportive care as a second-line treatment in patients with hepatocellular carcinoma who have been previously treated with sorafenib in the first-line setting.
	5.3.4 Traitements - AMM (FDA, EMA)
European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab), the First and Only PD-1 Checkpoint Inhibitor Approved in Europe, for Both First-Line and Previously-Treated Advanced Melanoma Patients [BMS] Approval based on CheckMate -066 trial demonstrating superior overall survival vs. dacarbazine in the first-line setting and CheckMate -037 trial showing improved response vs. chemotherapy in previously-treated patients, both at a consistent and well-established dose.
	5.4 Traitements - Economie
The Drug Abacus [In the Pipeline] Another one of the sliding factors in the model, development cost, I don't think should even be in there at all. Drugs should be evaluated by what they do, not how easy or hard they were to find and develop.
	6.11 Patients
Doctor Google is here to stay – and here to help [The Guardian] I resent Dr Google being the silent spoiler in my life but only until I recognise how the internet has allowed patients to seek counsel that would have been unthinkable in another era, and access to often high-quality information written with the patient in mind. My last few patients have probably learned more about clinical trials from the internet than from me.
	6.7 DMP, Big Data & applis
Why Hasn't Big Data Come to the Rescue in Clinical Data Unification? [Clinical Informatics News] An international pharmaceutical company spending $2 billion per year on clinical data research recently used this hybrid machine learning approach, employing automated sourcing of internal expertise to unify datasets from thousands of scientists in labs spread across the globe.
	6.7.2 Applis
For Wearables, Accurate Sensing Is Tricky [MIT Technology Review] There’s hope for wearable devices that actually take the types of measurements that would be helpful for health monitoring. But realizing that hope will probably mean moving on to radically new technologies. And it will certainly mean developing devices that are able to take a wider variety of measurements.
Taking control of cancer - from your mobile phone [ecancer - News] Eight partners from five European countries have come together to create intelligent "games" to allow cancer patients to take control of their illness... by harnessing the power of their mobile phones.